NURP.F Stock Overview
A biopharmaceutical company, develops drugs for the treatment of neurological disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$7.95 |
| 52 Week High | AU$17.21 |
| 52 Week Low | AU$6.61 |
| Beta | 2.17 |
| 11 Month Change | -9.76% |
| 3 Month Change | -20.50% |
| 1 Year Change | -21.83% |
| 33 Year Change | 476.09% |
| 5 Year Change | 359.54% |
| Change since IPO | 1,345.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| NURP.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -16.3% | 1.6% | 2.2% |
| 1Y | -21.8% | 9.9% | 31.6% |
Return vs Industry: NURP.F underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: NURP.F underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| NURP.F volatility | |
|---|---|
| NURP.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NURP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine NURP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NURP.F fundamental statistics | |
|---|---|
| Market cap | US$1.03b |
| Earnings (TTM) | US$76.22m |
| Revenue (TTM) | US$125.65m |
13.5x
P/E Ratio8.2x
P/S RatioIs NURP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NURP.F income statement (TTM) | |
|---|---|
| Revenue | AU$193.34m |
| Cost of Revenue | AU$32.90m |
| Gross Profit | AU$160.44m |
| Other Expenses | AU$43.15m |
| Earnings | AU$117.29m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 82.98% |
| Net Profit Margin | 60.67% |
| Debt/Equity Ratio | 0% |
How did NURP.F perform over the long term?
See historical performance and comparison